# Ipamorelin FAQ: Detection, Safety & Common Questions > Ipamorelin FAQ: is it banned by WADA, can it be detected in a drug test, what it does, the risks, and the CJC-1295 questions. Direct, cited answers. Twenty-two of the most-asked questions about detection, regulation, effects, and the CJC-1295 combination — each answered briefly and sourced. ## Is ipamorelin banned by WADA? Yes. Growth hormone secretagogues including ipamorelin are prohibited in sport at all times under the World Anti-Doping Agency Prohibited List, category S2. Detection is well established: a validated nano-LC method coupled to Orbitrap mass spectrometry screens ipamorelin in human urine down to 2-10 pg/mL [7], one of several accredited assays covering it [9]. ## Can ipamorelin be detected in a drug test? In anti-doping testing, yes — though not in a standard workplace panel. Accredited laboratories use mass-spectrometry methods that detect ipamorelin in urine at picogram-per-millilitre concentrations [7]. Its short ~2-hour terminal half-life in humans [2] narrows the detection window, but validated methods reliably identify the parent peptide and its metabolites [9][10]. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively triggers growth hormone release by activating the ghrelin receptor. Its founding 1998 study showed potent growth-hormone release in rats and swine without raising cortisol even at 200-fold its growth-hormone threshold [1] — the selectivity that defines it. It has never been approved as a drug. ## What does ipamorelin do for you? In studies, ipamorelin triggers a single pulse of growth hormone without raising cortisol [1], and in humans that pulse peaks about 40 minutes after dosing [2]. In rats it speeds bone growth [4]. Reported real-world effects — better sleep, faster recovery — are anecdotal and unverified by trials. It has no proven human therapeutic benefit; its one efficacy trial failed [3]. ## What is ipamorelin peptide? Ipamorelin peptide is the wholly synthetic pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from the older peptide GHRP-1 and stabilized against enzymatic breakdown. Molecular formula C38H49N9O5, weight about 711.9 daltons. It is not made by the body; it mimics ghrelin at the ghrelin receptor to release growth hormone, established as the first selective growth hormone secretagogue in 1998 [1]. ## What are the risks of ipamorelin? The documented risks are mostly gaps and class-level signals. The only Phase 2 trial showed no compound-specific safety signal in a 7-day window [3], but no long-term human safety data exist. A related ghrelin-receptor agonist caused heart-muscle degeneration in rats over 28 days [6], and the growth-hormone axis raises theoretical concerns around IGF-1 and glucose [4][13]. Research-grade purity is also unverified [17]. ## Does ipamorelin reduce belly fat? There is no controlled human trial showing ipamorelin reduces belly fat. Community reports describe a gradual, subtle lean-out over weeks to months, but those are anecdotal and confounded by diet and training. In a 2024 ferret study, ipamorelin blunted chemotherapy-driven weight loss by about 24% [5] — a weight-preserving effect in cachexia, not a fat-loss finding. Recent reviews classify it as investigational [17]. ## What are the downsides of ipamorelin? The central downside is that it has no proven benefit: its only Phase 2 trial, for postoperative ileus, missed its primary endpoint (25.3 vs 32.6 hours, p=0.15) [3]. Reported side effects include facial flushing, hunger, tingling, and mild water retention — all anecdotal. Structural concerns include unverified research-grade purity [17] and a class-level cardiac signal from a related compound [6]. ## Why is ipamorelin being discontinued? Ipamorelin was never an approved, marketed drug, so there is no approval to discontinue. Its clinical development effectively ended after the only Phase 2 trial — for postoperative ileus — missed its primary endpoint and no further trials followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access [11]. ## What does CJC-1295 and ipamorelin do? The CJC-1295 and ipamorelin combination pairs a growth-hormone-releasing-hormone analog (CJC-1295) with a ghrelin-receptor agonist (ipamorelin) to raise growth hormone through two complementary mechanisms [1]. A 2020 andrology review discusses where such secretagogues sit in practice and the gap between their marketing and any approved indication [11]. No controlled trial has tested the combination for any clinical outcome. ## Does ipamorelin increase IGF-1? Not always, and not in the short term. In the 15-day rat bone-growth study, ipamorelin raised bone growth with no measurable change in total IGF-1 [4], suggesting a partly local, pulse-driven effect. Over sustained protocols, growth-hormone-axis activation is mechanistically linked to IGF-1 elevation [1], which underlies the theoretical cancer caution — but ipamorelin-specific long-term human IGF-1 data do not exist. ## How does CJC-1295 ipamorelin work? CJC-1295 acts on the growth-hormone-releasing-hormone receptor while ipamorelin acts on the ghrelin receptor — two different doors to the same result, more growth hormone [1]. The pharmacological rationale for combining them is that these distinct, complementary mechanisms could produce a larger or more sustained growth-hormone response than either alone. That logic rests on each agent's single-agent pharmacology, not on any combination trial. ## How much CJC-1295 ipamorelin should I take? No controlled trial has ever tested the CJC-1295 ipamorelin combination, so there is no evidence-based dose [11]. The only repeated-dosing human ipamorelin data come from a failed hospital intravenous protocol [3], and the only other human data are acute pharmacokinetic infusions [2]. Recent reviews recommend confining ipamorelin to rigorous research protocols [16]. This site reports what was studied and does not provide a dose to take. ## Does CJC-1295 ipamorelin work? Each component has single-agent pharmacology supporting an acute growth-hormone response, and the combination's rationale is additive mechanisms [1]. But it has not been shown to "work" for body composition, recovery, or anti-aging in any controlled combination trial. Reviews characterize growth hormone secretagogues as outrunning their evidence [11] and classify ipamorelin as investigational with no reproducible human outcome data [16]. ## How to reconstitute CJC-1295 ipamorelin 5mg? Ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is typically refrigerated. These are general handling notes from the research-supply literature, not preparation instructions — and research-grade material from unregulated suppliers has unverified identity, purity, and sterility [17]. This site does not provide preparation or injection guidance. ## How long does ipamorelin stay in your system? Ipamorelin clears quickly: a terminal half-life of about 2 hours in healthy human volunteers, with a single growth-hormone pulse peaking near 40 minutes after dosing [2]. By the usual five-half-life rule of thumb, the parent peptide is largely cleared within roughly 10 hours — but validated anti-doping methods still detect it and its metabolites in urine at picogram levels [7][9]. See the [half-life page](/half-life) for detail. ## Does ipamorelin make you hungry? Sometimes. Ipamorelin acts on the ghrelin receptor — the body's own hunger-signal receptor — so an appetite bump is mechanistically plausible [15], and increased hunger is occasionally reported in the hours after dosing. A 2026 sports-medicine review classifies ipamorelin as an investigational secretagogue [16]; community accounts call the appetite effect milder than with GHRP-6. No human appetite data exist at research-use doses. ## Will I gain weight on ipamorelin? There is no human trial answering this directly. In mice, ipamorelin increased fat mass and leptin partly independent of the growth-hormone axis after two weeks [14], and ghrelin-receptor agonists drive feeding [15] — so weight gain is mechanistically possible through appetite. But the only human efficacy trial concerned bowel recovery, not body weight, and reported no compound-specific signal [3]. Community reports are mixed and anecdotal. ## Does ipamorelin increase appetite? It can, by mechanism. Ipamorelin activates the ghrelin receptor, and central ghrelin-receptor agonism activates the brain's appetite centers and induces feeding in animals [15]. A 2026 review treats ipamorelin as an investigational growth-hormone-axis secretagogue [16]. Appetite increase is among the occasionally-reported real-world effects, described as milder than with older peptides — but unverified by human data at research-use doses. ## What does ipamorelin peptide do? Ipamorelin peptide selectively activates the ghrelin receptor on pituitary cells to release a pulse of growth hormone, without meaningfully raising cortisol or prolactin [1]. In humans that pulse peaks about 40 minutes after dosing and clears with a ~2-hour half-life [2]. In rats it speeds bone growth [4]. Its real-world reputation for sleep and recovery is anecdotal; its one human efficacy trial failed [3]. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes (0.67 h) after an intravenous dose in humans [2]. For the subjective effects people report — better sleep, recovery — community accounts describe first changes within one to two weeks of a routine, with body-composition shifts noted later, around weeks five to twelve. Those timelines are anecdotal, not from controlled studies, and vary widely. ## Does ipamorelin cause water retention? Mild water retention and puffiness are occasionally reported, usually in the first few weeks and generally described as milder than with older growth-hormone-releasing peptides. The mechanism is plausible: growth-hormone excess promotes sodium and water retention [6]. But this is an anecdotal community signal, not a finding from a controlled ipamorelin trial — the one Phase 2 trial recorded no compound-specific safety signal in its short window [3]. --- A naturalist's watch over the ipamorelin record — the molecule the anti-doping labs learned to catch at picogram traces, its single failed human trial kept openly in view, and community reports fenced off as unverified; no clinic, pharmacy, or product stands behind this page, and nothing here is dosed, prescribed, or sold.